TapewireFind a company

organization · Reporting owner

Third Rock Ventures III, L.P.

Disclosed activity across 11 companies

Tapewire entity
117227
SEC CIK
0001569705

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Decibel Therapeutics, Inc.[DBTX] · Entity 10945810% ownerFebruary 11, 2021February 12, 2021
Global Blood Therapeutics, Inc.GBT · Entity 12322010% ownerMarch 02, 2017March 06, 2017
Jounce Therapeutics, Inc.JNCE · Entity 1575410% ownerNovember 12, 2021November 16, 2021
MyoKardia, Inc.MYOK · Entity 14520610% ownerJanuary 03, 2018January 05, 2018
Neon Therapeutics, Inc.NTGN · Entity 14943310% ownerJune 29, 2018July 03, 2018
Nurix Therapeutics, Inc.NRIX · Entity 115610% ownerMay 06, 2021May 10, 2021
Relay Therapeutics, Inc.RLAY · Entity 404410% ownerJanuary 12, 2021January 14, 2021
Revolution Medicines, Inc.RVMD · Entity 60610% ownerJune 08, 2022June 10, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Decibel Therapeutics, Inc.

Report date February 11, 2021 · Filed February 12, 2021

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, Levin Mark J, STARR KEVIN P, Tepper Robert I

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect47,169 Reported balance Holding disclosure · report date 2021-02-11 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 47,169

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series A Convertible Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2021-02-11 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F2: The Series A Preferred Stock is convertible into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2021-02-11 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F3: The Series C Preferred Stock is convertible into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series D Convertible Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2021-02-11 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F4: The Series D Preferred Stock is convertible into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F2: The Series A Preferred Stock is convertible into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F3: The Series C Preferred Stock is convertible into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date

F4: The Series D Preferred Stock is convertible into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect6,475,191 Reported balance After 2017-03-02 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2017-03-02 · Sale · Disposed 1,000,000 · Balance 6,475,191

F1: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect285,713 Reported balance After 2017-03-02 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2017-03-02 · Sale · Disposed 1,000,000 · Balance 285,713

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect164,387 Reported balance After 2017-03-02 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2017-03-02 · Sale · Disposed 27,115 · Balance 164,387

F3: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.30, inclusive. Levin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (6) to this Form 4.

F4: These shares are directly held by Levin.

Common StockSEC Table I · non-derivativeDirect157,108 Reported balance After 2017-03-02 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2017-03-02 · Sale · Disposed 7,279 · Balance 157,108

F5: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.35 to $28.275, inclusive.

F4: These shares are directly held by Levin.

Common StockSEC Table I · non-derivativeDirect146,208 Reported balance After 2017-03-02 transaction · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · 2017-03-02 · Sale · Disposed 10,900 · Balance 146,208

F6: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.975, inclusive.

F4: These shares are directly held by Levin.

Common StockSEC Table I · non-derivativeDirect82,544 Reported balance Holding disclosure · report date 2017-03-02 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 82,544

F7: These shares are directly held by Starr.

Common StockSEC Table I · non-derivativeDirect191,501 Reported balance Holding disclosure · report date 2017-03-02 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 191,501

F8: These shares are directly held by Tepper.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.30, inclusive. Levin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (6) to this Form 4.

F4: These shares are directly held by Levin.

F5: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.35 to $28.275, inclusive.

F6: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.975, inclusive.

F7: These shares are directly held by Starr.

F8: These shares are directly held by Tepper.

Jounce Therapeutics, Inc.

Report date November 12, 2021 · Filed November 16, 2021

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Tepper Robert I, Levin Mark J

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,148,780 Reported balance After 2021-11-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-11-12 · Sale · Disposed 1,900,000 · Balance 1,148,780

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,697,829 Reported balance Holding disclosure · report date 2021-11-12 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,697,829

F3: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote284,344 Reported balance Holding disclosure · report date 2021-11-12 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 284,344

F4: The shares are directly held by Levin.

Common StockSEC Table I · non-derivativeIndirectSee footnote283,850 Reported balance Holding disclosure · report date 2021-11-12 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 283,850

F5: The shares are directly held by Starr.

Common StockSEC Table I · non-derivativeIndirectSee footnote283,858 Reported balance Holding disclosure · report date 2021-11-12 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 283,858

F6: The shares are directly held by Tepper.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F4: The shares are directly held by Levin.

F5: The shares are directly held by Starr.

F6: The shares are directly held by Tepper.

MyoKardia, Inc.

Report date January 03, 2018 · Filed January 05, 2018

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, Levin Mark J, Tepper Robert I

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect680,272 Reported balance After 2018-01-03 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2018-01-03 · Sale · Disposed 816,326 · Balance 680,272

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect201,042 Reported balance Holding disclosure · report date 2018-01-03 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 201,042

F3: Third Rock Ventures II, L.P. ("TRV II") directly holds 2,885,104 shares of Common Stock of the Issuer. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F4: The shares are directly held by Levin.

Common StockSEC Table I · non-derivativeDirect221,042 Reported balance Holding disclosure · report date 2018-01-03 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 221,042

F3: Third Rock Ventures II, L.P. ("TRV II") directly holds 2,885,104 shares of Common Stock of the Issuer. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F5: The shares are directly held by Tepper.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: Third Rock Ventures II, L.P. ("TRV II") directly holds 2,885,104 shares of Common Stock of the Issuer. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F4: The shares are directly held by Levin.

F5: The shares are directly held by Tepper.

Neon Therapeutics, Inc.

Report date June 29, 2018 · Filed July 03, 2018

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Levin Mark J

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,741,636 Last balance in matching sequence After 2018-06-29 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2018-06-29 · Conversion · Acquired 8,999,999 · Balance 9,399,999

F1: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Row 2 · 2018-06-29 · Conversion · Acquired 341,637 · Balance 9,741,636

F3: Represents the total number of shares of Common Stock received by TRV III upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-06-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2018-06-29 · Conversion · Disposed 45,000,000 · Balance 0

F2: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-06-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2018-06-29 · Conversion · Disposed 1,708,185 · Balance 0

F2: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F3: Represents the total number of shares of Common Stock received by TRV III upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F4: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Nurix Therapeutics, Inc.

Report date May 06, 2021 · Filed May 10, 2021

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Tepper Robert I, Levin Mark J

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,422,549 Reported balance After 2021-05-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-05-06 · Other · Disposed 1,085,784 · Balance 3,422,549

F1: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote78,118 Reported balance Holding disclosure · report date 2021-05-06 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 78,118

F3: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote8,677 Reported balance Holding disclosure · report date 2021-05-06 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 8,677

F4: The shares are directly held by Levin Family 2014 Irrevocable Trust. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote86,798 Reported balance Holding disclosure · report date 2021-05-06 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 86,798

F5: The shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote86,799 Reported balance Holding disclosure · report date 2021-05-06 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 86,799

F6: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

F4: The shares are directly held by Levin Family 2014 Irrevocable Trust. Includes Shares received in the distributions described in footnote (1) above.

F5: The shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

F6: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect7,739,918 Last balance in matching sequence After 2021-01-13 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 1 · 2021-01-12 · Sale · Disposed 1,500,000 · Balance 9,051,115

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 2 · 2021-01-13 · Sale · Disposed 1,247,873 · Balance 7,803,242

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 3 · 2021-01-13 · Sale · Disposed 8,727 · Balance 7,794,515

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 4 · 2021-01-13 · Sale · Disposed 42,860 · Balance 7,751,655

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 5 · 2021-01-13 · Sale · Disposed 4,325 · Balance 7,747,330

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 6 · 2021-01-13 · Sale · Disposed 7,412 · Balance 7,739,918

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes0 Last balance in matching sequence After 2021-01-14 transaction · row 12 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 7 · 2021-01-13 · Sale · Disposed 805,050 · Balance 2,006,147

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 8 · 2021-01-13 · Sale · Disposed 5,630 · Balance 2,000,517

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 9 · 2021-01-13 · Sale · Disposed 27,650 · Balance 1,972,867

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 10 · 2021-01-13 · Sale · Disposed 2,791 · Balance 1,970,076

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 11 · 2021-01-13 · Sale · Disposed 4,782 · Balance 1,965,294

F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 12 · 2021-01-14 · Sale · Disposed 1,965,294 · Balance 0

F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).

F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).

F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Revolution Medicines, Inc.

Report date June 08, 2022 · Filed June 10, 2022

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, Tepper Robert I

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,104,130 Reported balance After 2022-06-08 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2022-06-08 · Sale · Disposed 419,901 · Balance 5,104,130

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares

Common StockSEC Table I · non-derivativeDirect129,258 Reported balance Holding disclosure · report date 2022-06-08 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 129,258

F4: The shares are directly held by Tepper.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance Holding disclosure · report date 2022-06-08 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 0

F3: Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of Common Stock of the Issuer. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons and TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares

F3: Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of Common Stock of the Issuer. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons and TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4: The shares are directly held by Tepper.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Fulcrum Therapeutics, Inc.

Report date December 13, 2022 · Filed December 15, 2022

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, Tepper Robert I

Section 16 reporting ended · disclosed 2022-12-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,962,202 Reported balance After 2022-12-13 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2022-12-13 · Other · Disposed 2,000,000 · Balance 1,962,202

F1: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect156,189 Reported balance Holding disclosure · report date 2022-12-13 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 156,189

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,343,154 Reported balance Holding disclosure · report date 2022-12-13 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,343,154

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

PLIANT THERAPEUTICS, INC.

Report date November 29, 2022 · Filed December 01, 2022

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, Tepper Robert I

Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,839,160 Reported balance After 2022-11-29 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2022-11-29 · Other · Disposed 2,000,000 · Balance 1,839,160

F1: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect229,504 Reported balance Holding disclosure · report date 2022-11-29 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 229,504

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,132,867 Reported balance Holding disclosure · report date 2022-11-29 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,132,867

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Voyager Therapeutics, Inc.

Report date February 02, 2023 · Filed February 06, 2023

Jointly reported with Third Rock Ventures GP III, L.P., TRV GP III, LLC, Tepper Robert I

Section 16 reporting ended · disclosed 2023-02-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,185,291 Reported balance After 2023-02-02 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2023-02-02 · Other · Disposed 1,500,000 · Balance 3,185,291

F1: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect86,265 Reported balance Holding disclosure · report date 2023-02-02 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 86,265

F3: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 20, 2020 Filed Jul 21, 2020 19:23 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 ConversionCommon Stock 2,793,770 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-019850 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,793,770

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · ownership.nature: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F4 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV").

F5 · ownership.nature: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F7 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
July 20, 2020 Filed Jul 21, 2020 19:23 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 ConversionCommon Stock 9,970,454 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-019850 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,970,454

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III").

F2 · ownership.direct: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of the reporting persons, except for TRV III, disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3 · ownership.direct: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F7 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 21:01 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 ConversionSeries A Preferred Stock · Derivative 15,250,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-015874 · doc4.xml · derivative · entry 4

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,132,867 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F6 · ownership.nature: These shares are directly held by Third Rock Ventures IV.

F7 · ownership.nature: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8 · ownership.nature: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 21:01 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 ConversionSeries A Preferred Stock · Derivative 39,750,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-015874 · doc4.xml · derivative · entry 3

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,559,440 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV III.

F4 · ownership.direct: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8 · ownership.direct: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 21:01 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 ConversionCommon Stock 2,132,867 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-015874 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,132,867

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures IV, L.P. ("TRV IV") upon conversion of the preferred stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2 · price: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F6 · ownership.nature: These shares are directly held by Third Rock Ventures IV.

F7 · ownership.nature: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8 · ownership.nature: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 21:01 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 ConversionCommon Stock 5,559,440 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-015874 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,839,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon conversion of the preferred stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2 · price: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV III.

F4 · ownership.direct: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8 · ownership.direct: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
February 18, 2020 Filed Feb 18, 2020 17:21 UTC Revolution Medicines, Inc. RVMD · Entity 606 ConversionSeries B Preferred Stock · Derivative 1,909,317 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-004930 · doc4.xml · derivative · entry 6

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,909,317 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F5 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 18, 2020 Filed Feb 18, 2020 17:21 UTC Revolution Medicines, Inc. RVMD · Entity 606 ConversionSeries C Preferred Stock · Derivative 49,879 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-004930 · doc4.xml · derivative · entry 5

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,879 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 18, 2020 Filed Feb 18, 2020 17:21 UTC Revolution Medicines, Inc. RVMD · Entity 606 ConversionSeries B Preferred Stock · Derivative 342,505 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-004930 · doc4.xml · derivative · entry 4

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 342,505 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 18, 2020 Filed Feb 18, 2020 17:21 UTC Revolution Medicines, Inc. RVMD · Entity 606 ConversionSeries A Preferred Stock · Derivative 8,220,641 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-004930 · doc4.xml · derivative · entry 3

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,220,641 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 18, 2020 Filed Feb 18, 2020 17:21 UTC Revolution Medicines, Inc. RVMD · Entity 606 ConversionCommon Stock 1,909,317 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-004930 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,909,317

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures II, L.P. ("TRV II") upon conversion of the Series B Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 18, 2020 Filed Feb 18, 2020 17:21 UTC Revolution Medicines, Inc. RVMD · Entity 606 ConversionCommon Stock 8,613,025 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-004930 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,024,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon conversion of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 22, 2019 Filed Jul 22, 2019 16:34 UTC Fulcrum Therapeutics, Inc. FULC · Entity 5969 ConversionSeries A Preferred Stock · Derivative 0 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-020026 · doc4.xml · derivative · entry 4

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2 · shares: As of the date of this filing, Third Rock Ventures IV, L.P. ("TRV IV") holds 2,261,904 shares of Common Stock issued upon conversion of 15,833,333 shares of Series A Preferred Stock. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Abbie Celniker, Ph.D., Tepper, Alexis Borisy, Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV IV LLC who collectively make voting and investment decisions with respect to shares held by TRV IV LP. Tepper disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

F3 · derivative.exercise_date: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3 · derivative.expiration_date: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2 · derivative.underlying_shares: As of the date of this filing, Third Rock Ventures IV, L.P. ("TRV IV") holds 2,261,904 shares of Common Stock issued upon conversion of 15,833,333 shares of Series A Preferred Stock. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Abbie Celniker, Ph.D., Tepper, Alexis Borisy, Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV IV LLC who collectively make voting and investment decisions with respect to shares held by TRV IV LP. Tepper disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

F1 · ownership.direct: The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III LP"). The general partner of TRV GP III LP is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III LP, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 22, 2019 Filed Jul 22, 2019 16:34 UTC Fulcrum Therapeutics, Inc. FULC · Entity 5969 ConversionSeries A Preferred Stock · Derivative 39,166,667 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-020026 · doc4.xml · derivative · entry 3

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,595,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3 · derivative.exercise_date: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3 · derivative.expiration_date: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · ownership.direct: The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III LP"). The general partner of TRV GP III LP is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III LP, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 22, 2019 Filed Jul 22, 2019 16:34 UTC Fulcrum Therapeutics, Inc. FULC · Entity 5969 PurchaseCommon Stock 81,250 $16.00 $1,300,000.00
Disclosure

SEC source: 0000899243-19-020026 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,962,202

F2 · balance_after: As of the date of this filing, Third Rock Ventures IV, L.P. ("TRV IV") holds 2,261,904 shares of Common Stock issued upon conversion of 15,833,333 shares of Series A Preferred Stock. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Abbie Celniker, Ph.D., Tepper, Alexis Borisy, Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV IV LLC who collectively make voting and investment decisions with respect to shares held by TRV IV LP. Tepper disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

F1 · ownership.direct: The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III LP"). The general partner of TRV GP III LP is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III LP, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 22, 2019 Filed Jul 22, 2019 16:34 UTC Fulcrum Therapeutics, Inc. FULC · Entity 5969 ConversionCommon Stock 5,595,238 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020026 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,880,952

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2 · balance_after: As of the date of this filing, Third Rock Ventures IV, L.P. ("TRV IV") holds 2,261,904 shares of Common Stock issued upon conversion of 15,833,333 shares of Series A Preferred Stock. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Abbie Celniker, Ph.D., Tepper, Alexis Borisy, Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV IV LLC who collectively make voting and investment decisions with respect to shares held by TRV IV LP. Tepper disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

F1 · ownership.direct: The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III LP"). The general partner of TRV GP III LP is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III LP, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
September 19, 2018 Filed Sep 19, 2018 21:41 UTC Voyager Therapeutics, Inc. VYGR · Entity 6271 OtherCommon Stock 1,500,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-024777 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,391,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on September 19, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on September 19, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:28 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 ConversionSeries B Preferred Stock · Derivative 1,708,185 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-043853 · a4.xml · derivative · entry 4

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 341,637 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F2 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F2 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F2 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:28 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 ConversionSeries A Preferred Stock · Derivative 45,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-043853 · a4.xml · derivative · entry 3

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,999,999 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F2 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F2 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F2 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:28 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 ConversionCommon Stock 341,637 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-043853 · a4.xml · nonDerivative · entry 2

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,741,636

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: Represents the total number of shares of Common Stock received by TRV III upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:28 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 ConversionCommon Stock 8,999,999 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-043853 · a4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,399,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 20, 2018 Filed Jun 21, 2018 20:05 UTC Voyager Therapeutics, Inc. VYGR · Entity 6271 OtherCommon Stock 1,500,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-017587 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,891,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
January 03, 2018 Filed Jan 5, 2018 16:30 UTC MyoKardia, Inc. MYOK · Entity 145206 SaleCommon Stock 816,326 $42.00 $34,285,773.63
Disclosure

SEC source: 0000899243-18-000584 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 680,272

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
April 12, 2017 Filed Apr 14, 2017 20:00 UTC Voyager Therapeutics, Inc. VYGR · Entity 6271 OtherCommon Stock 920,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-010312 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,391,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 10,900 $28.73 $313,146.10
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 5

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,208

F6 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.975, inclusive.

F4 · ownership.direct: These shares are directly held by Levin.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 7,279 $27.69 $201,526.39
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 4

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,108

F5 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.35 to $28.275, inclusive.

F4 · ownership.direct: These shares are directly held by Levin.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 27,115 $26.95 $730,803.48
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 3

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,387

F3 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.30, inclusive. Levin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (6) to this Form 4.

F4 · ownership.direct: These shares are directly held by Levin.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 1,000,000 $25.50 $25,500,000.00
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,713

F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 1,000,000 $25.50 $25,500,000.00
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,475,191

F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 01, 2017 Filed Feb 3, 2017 17:13 UTC Jounce Therapeutics, Inc. JNCE · Entity 15754 ConversionSeries A Preferred Stock · Derivative 11,250,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-002744 · doc4.xml · derivative · entry 4

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,048,780 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F5 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 01, 2017 Filed Feb 3, 2017 17:13 UTC Jounce Therapeutics, Inc. JNCE · Entity 15754 ConversionSeries A Preferred Stock · Derivative 35,750,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-002744 · doc4.xml · derivative · entry 3

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,688,344 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 01, 2017 Filed Feb 3, 2017 17:13 UTC Jounce Therapeutics, Inc. JNCE · Entity 15754 ConversionCommon Stock 3,048,780 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-002744 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,048,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon conversion of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F3 · price: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F5 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
February 01, 2017 Filed Feb 3, 2017 17:13 UTC Jounce Therapeutics, Inc. JNCE · Entity 15754 ConversionCommon Stock 9,688,344 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-002744 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,230,349

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures II, L.P. ("TRV II") upon conversion of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F3 · price: Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
December 19, 2016 Filed Dec 21, 2016 22:49 UTC Voyager Therapeutics, Inc. VYGR · Entity 6271 OtherCommon Stock 750,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-16-036195 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,311,176

F1 · kind: On December 19, 2016, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 750,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: On December 19, 2016, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 750,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
November 14, 2016 Filed Nov 16, 2016 16:12 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 1,000,000 $19.36 $19,360,000.00
Disclosure

SEC source: 0000899243-16-033679 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,285,713

F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
November 14, 2016 Filed Nov 16, 2016 16:12 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 1,000,000 $19.36 $19,360,000.00
Disclosure

SEC source: 0000899243-16-033679 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,475,191

F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.